Market capitalization | $382.74m |
Enterprise Value | $-137.63m |
EV/FCF (TTM) EV/FCF | 1.37 |
P/B ratio (TTM) P/B ratio | 0.68 |
Free Cash Flow (TTM) Free Cash Flow | $-100.38m |
Cash position | $520.37m |
P/E forward | negative |
Short interest | 9.21% |
As a Free StocksGuide user, you can view scores for all 6,841 stocks worldwide.
6 Analysts have issued a ITeos Therapeutics Inc forecast:
6 Analysts have issued a ITeos Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 35 35 |
178%
178%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -158 -158 |
5%
5%
|
EBIT (Operating Income) EBIT | -160 -160 |
6%
6%
|
Net Profit | -134 -134 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Michel Detheux |
Employees | 173 |
Founded | 2012 |
Website | www.iteostherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.